Physician profile
Gregory P Kezele
NPI 1972563997
$1,797.94
in general payments reported to CMS, 2019-2025
20 companies · $635 in 2025
The $635 reported for 2025 was more than what 82% of Phlebology providers received nationally (typical 2025 total: $141).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $96.92 · 2021: $158 · 2022: $147 · 2023: $110 · 2024: $313 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $296.27 | 2019-2025 | Collagenase Santyl, Renasys Go V2 Home |
| Kerecis Limited | $255.13 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Melinta Therapeutics, LLC | $227.72 | 2019 | |
| Organogenesis INC. | $199.51 | 2020-2025 | Apligraf |
| Convatec INC. | $109.69 | 2023 | |
| Bard Peripheral Vascular, INC. | $106.75 | 2025 | Venclose Maven Catheter |
| Sun Pharmaceutical Industries INC. | $89.73 | 2022-2025 | |
| Mimedx Group, INC. | $87.57 | 2024 | |
| Tactile Systems Technology INC | $62.59 | 2025 | Flexitouch Plus, Nimbl |
| Boston Scientific Corporation | $61.47 | 2024-2025 | Varithena Administration Pack |
| Regeneron Healthcare Solutions, INC. | $56.37 | 2021-2025 | Libtayo, Dupixent |
| Revance Therapeutics, INC. | $53.83 | 2025 | Daxxify |
| Integra Lifesciences Corporation | $39.52 | 2024-2025 | Tcc-Ez |
| Lilly USA, LLC | $37.00 | 2022-2024 | Taltz |
| Janssen Biotech, INC. | $26.98 | 2025 | Tremfya |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.00 | 2024 | Otezla |
| Incyte Corporation | $18.15 | 2021 | |
| Biofrontera INC. | $15.69 | 2025 | Ameluz |
| Vyne Pharmaceuticals INC. | $14.79 | 2020 | |
| Biocompatibles, INC. | $14.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Kezele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.